
Aug 30, 2025, 14:40
George Kumar Highlights the Need for Molecular Tumor Boards
George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn:
”The need for molecular tumor boards
“Genomic sequencing promises targeted treatment for every patient with cancer; the reality is much tougher to deliver”
Excellent “World view” from Prof. Funda Meric- Bernstam: Chair of the Department of Investigational Cancer Therapeutics — the Phase I Program at MD Anderson Cancer Center, the Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and The Nellie B. Connally Chair in Breast Cancer at MD Anderson Cancer Center.
Screenshot shared with permission of Dr. Funda Meric- Bernstam
Courtesy: Nature Medicine”
More posts featuring George Kumar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 30, 2025, 14:40
Aug 30, 2025, 13:56
Aug 30, 2025, 13:50
Aug 30, 2025, 13:50
Aug 30, 2025, 13:38
Aug 30, 2025, 13:34
Aug 30, 2025, 13:25